newsnews.ai

Cerebras Debuts on Nasdaq at $350, Surpassing $100 Billion Market Cap

The Sunnyvale-based AI chipmaker's stock opened significantly above its IPO price, marking one of the largest Nasdaq debuts of 2026.

By NewsNews AI
grayscale photo of people walking towards building
grayscale photo of people walking towards building·Photo: Anthony Tyrrell on Unsplashunsplash

Market Debut and Valuation

Cerebras Systems Inc. (CBRS) began trading on the Nasdaq on Thursday, opening at $350 per share. This opening price pushed the company's market capitalization beyond $100 billion. The stock's initial trading price represents a significant increase over its initial public offering (IPO) price.

According to company filings, Cerebras priced its IPO at $185.00 per share. The offering consisted of 30 million shares, allowing the Sunnyvale, California-based chipmaker to raise $5.55 billion. This figure marks the largest Nasdaq debut of 2026 thus far.

Industry Context

Cerebras is entering the public market during a period of high investor demand for artificial intelligence infrastructure. CNBC reports that the company is leveraging a "bull market for silicon," positioning itself as one of the most prominent "pureplay AI IPOs" to date.

Reuters describes the current environment as one of "investor euphoria" for companies central to the artificial intelligence boom.

IPO Pipeline and Timing

The Cerebras listing follows a period of increased activity in the U.S. IPO market. In the week preceding the debut, five listings raised a combined $4.5 billion, including two billion-dollar deals and the largest U.S. biotech IPO in history.

Cerebras filed its official paperwork on Monday, increasing its initial offering terms ahead of the Thursday debut.

Sources (6)Open

Topics

How NewsNews AI made this storyOpen

NewsNews AI researched this story across 6 sources, drafted it, and ran the result through an independent editorial pass. It cleared editorial review on first pass.

  • 6 sources cited · linked in full at the bottom of the article
  • Image license verified · unsplash
  • Independent editorial pass · approved

From the editor

Verified all key claims against source snippets. Opening price of $350 and $100B+ market cap are supported by source 1. IPO pricing at $185/share, 30 million shares, and $5.55B raise are supported by source 5. IPO pipeline context (five listings, $4.5B combined, largest US biotech IPO) is supported by source 3. Reuters "investor euphoria" quote is supported by source 6. CNBC "bull market for silicon" and "pureplay AI IPOs" quotes are supported by source 1. The MSN headline (source 4) corroborates the opening price being significantly above IPO price. All key facts cite appropriate sources. No fabrications, contradictions, or unsupported claims detected.

More about our editorial process

Feedback

We want to hear from you, especially when something is wrong. No signup, no email required.

Keep reading